Cannabidiol oral solution for Psychosis

"This trial is looking for enrollees between the ages of 16-30. In contrast, there are 130 similar studies available for patients under 18 and 329 for those above 65."

"Yes, this is an ongoing recruitment according to the information detailed on clinicaltrials.gov. The listing for this trial was created on July 1st 2021 and edited June 4th 2021."

"Cannabidiol oral solution has received a Phase 3 designation, meaning that while there is some efficacy data available, the primary focus is on safety."

"That is correct. The online information regarding this study confirms that it is still recruiting patients. This particular trial was first advertised on July 1st, 2021 and the most recent update was June 4th, 2021. They are looking for a total of 120 individuals at 2 locations."

"83 different clinical trials are currently underway to study the effects of Cannabidiol oral solution. This includes 18 Phase 3 trials. While many of these studies hail from Ribeirao Preto and Sao Paulo, 311 locations worldwide are participating in research for Cannabidiol oral solution."

"This trial is looking for 120 individuals, all of whom must meet the following criteria: Aged between 16 and 30, currently have a mental disorder, clinically stable for at least 2 months, first episode psychosis participants will have been maintained on current antipsychotic for at least 6 weeks with no change in antipsychotic dose for the previous 4 weeks while APS participants will be on the same treatment regimen (psychosocial or pharmacologic) for 4 weeks, exhibit no more than moderate levels of positive symptoms (defined by ratings of ≤ 4) on PANSS items P1 (delusions), P2 (conceptual disorganization),"